| Title |
Enteropathy-Associated T-Cell Lymphoma
|
|---|---|
| Published in |
Current Hematologic Malignancy Reports, November 2016
|
| DOI | 10.1007/s11899-016-0357-7 |
| Pubmed ID | |
| Authors |
Sarah Ondrejka, Deepa Jagadeesh |
| Abstract |
Enteropathy-associated T-cell lymphoma is a rare neoplasm with uniformly aggressive features that arises from intestinal T-cells. There is strong evidence supporting its association as a dire complication of celiac disease. The clinical presentation can vary from malabsorption and abdominal pain to an acute abdominal emergency. Originally, it was divided into types I and II in World Health Organization (WHO) classification schemes, reflective of epidemiology and differences in clinicopathologic features. The debate over the degree of separation of the two types is ongoing as new data emerges regarding the pathogenetics. The low incidence and variable patient factors are major barriers in conducting clinical trials and establishing standard treatment regimens. Yet, the collective experience demonstrates favorable outcomes with combination chemotherapy followed by an autologous hematopoietic stem cell transplant in patients who can tolerate such treatment. The prognosis remains dismal; thus, future research studies are warranted to identify effective novel therapies that can improve outcomes in this rare disease entity. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 19% |
| Student > Bachelor | 6 | 11% |
| Student > Master | 6 | 11% |
| Other | 5 | 9% |
| Student > Postgraduate | 4 | 8% |
| Other | 8 | 15% |
| Unknown | 14 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 45% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Nursing and Health Professions | 3 | 6% |
| Veterinary Science and Veterinary Medicine | 2 | 4% |
| Immunology and Microbiology | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 16 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2022.
All research outputs
#7,012,526
of 22,958,253 outputs
Outputs from Current Hematologic Malignancy Reports
#152
of 429 outputs
Outputs of similar age
#127,852
of 417,139 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#1
of 3 outputs
Altmetric has tracked 22,958,253 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 429 research outputs from this source. They receive a mean Attention Score of 5.0. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 417,139 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them